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Abstract
Galloway-Mowat syndrome (GAMOS) is a severe autosomal-recessive disease characterized by 
the combination of early-onset steroid-resistant nephrotic syndrome (SRNS) and microcephaly 
with brain anomalies. To date, mutations of WDR73 are the only known monogenic cause of 
GAMOS and in most affected individuals the molecular diagnosis remains elusive. We here 
identify recessive mutations of OSGEP, TP53RK, TPRKB, or LAGE3, encoding the 4 subunits of 
the KEOPS complex in 33 individuals of 30 families with GAMOS. CRISPR/Cas9 knockout in 
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zebrafish and mice recapitulates the human phenotype of microcephaly and results in early 
lethality. Knockdown of OSGEP, TP53RK, or TPRKB inhibits cell proliferation, which human 
mutations fail to rescue, and knockdown of either gene activates DNA damage response signaling 
and induces apoptosis. OSGEP and TP53RK molecularly interact and co-localize with the actin-
regulating ARP2/3 complex. Furthermore, knockdown of OSGEP and TP53RK induces defects of 
the actin cytoskeleton and reduces migration rate of human podocytes, an established intermediate 
phenotype of SRNS. We thus identify 4 novel monogenic causes of GAMOS, describe the first 
link between KEOPS function and human disease, and delineate potential pathogenic mechanisms.
RESULTS
Mutations of KEOPS complex encoding genes in patients with Galloway-Mowat syndrome
Galloway-Mowat syndrome (GAMOS, MIM #251300), a distinct renal-neurological disease, 
is characterized by early-onset nephrotic syndrome (NS) associated with microcephaly, brain 
anomalies, and developmental delay.1–3 Seeking additional monogenic causes of NS we 
performed homozygosity mapping4 and whole exome sequencing (WES)5 in 91 families. In 
consanguineous family B57 (Supplementary Fig. 1A) with GAMOS we detected a 
homozygous missense mutation (p.Ile14Phe) in the gene OSGEP (Supplementary Table 1, 
Fig. 1, Supplementary Fig. 1–2). OSGEP encodes the tRNA N6-adenosine 
threonylcarbamoyltransferase protein OSGEP, a unit of the highly conserved KEOPS 
complex (Kinase, Endopeptidase and Other Proteins of small Size). The KEOPS complex 
contains 4 subunits LAGE3, OSGEP, TP53RK, and TPRKB. It regulates a universal 
chemical modification of tRNAs that is necessary for translational accuracy and efficiency.
6–9
 Other known functions relate to control of telomere length, genome maintenance,10,11 
and regulation of gene transcription.12 Furthermore, the KEOPS complex has been 
implicated in telomere associated DNA damage response (DDR) signaling, and exhibits 
intrinsic DNA binding ability.13,14
Using WES and high-throughput exon sequencing,15,16 we then screened the coding regions 
of OSGEP, TP53RK, TPRKB and LAGE3 in 907 individuals with NS including 91 
individuals with GAMOS. We discovered mutations in all 4 genes in 33 individuals with 
GAMOS from 30 different families (Supplementary Table 1, Supplementary Fig. 1–3). We 
did not detect mutations in families with isolated NS. Specifically, we discovered recessive 
OSGEP mutations in 22 families (15 different alleles), TP53RK mutations in 3 families (4 
different alleles), TPRKB mutations in 2 families (2 different alleles), and LAGE3 mutations 
in 3 families (3 different alleles) (Fig. 1, Supplementary Fig. 1–3, Supplementary Table 1). 
Inheritance was autosomal recessive or X-linked (LAGE3). Multiple OSGEP mutations were 
shared between different families from distinct ethnicities, most likely representing 
geographic founder alleles from Iran, Taiwan, and Europe (Supplementary Table 1).
Clinical features in KEOPS complex mutations
Phenotypically, all individuals with mutations in any of the 4 KEOPS genes had primary 
microcephaly, developmental delay, propensity for seizures, and NS of early onset (Fig. 1, 
Supplementary Fig. 4, Table 1, Supplementary Table 1). Most patients died in early 
childhood. Several individuals were noted to have facial dysmorphism sometimes with 
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features of progeria, and skeletal abnormalities such as arachnodactyly. The most frequently 
observed brain anomalies included a spectrum of gyration abnormalities ranging from 
lissencephaly to pachygyria and polymicrogyria, and cerebellar hypoplasia (Fig. 1, 
Supplementary Fig. 4, Table 1, Supplementary Table 1).
Renal biopsy revealed focal-segmental glomerulosclerosis (FSGS), its developmental 
equivalent, diffuse mesangial sclerosis (DMS),17 or other glomerular lesions in 16 
individuals in whom a renal biopsy was performed. Electron microscopy revealed partial 
podocyte foot process effacement (Fig. 1, Supplementary Fig. 4, Table 1, Supplementary 
Table 1). Because of the early onset of nephrotic syndrome, only in 3 individuals a 
therapeutic attempt was made with corticoids or cyclosporin A. However, none of these 
individuals responded to any treatment regimen as expected in FSGS or DMS.18
We thereby discovered recessive mutations in any of the 4 genes encoding KEOPS complex 
proteins as novel causes of Galloway-Mowat syndrome. We termed these variants of 
GAMOS due to mutations in LAGE3, OSGEP, TP53RK, or TPRKB, ‘GAMOS 2’, 
‘GAMOS 3’, ‘GAMOS 4’ and ‘GAMOS 5’, respectively. Thus, we made the surprising 
discovery, that specific recessive mutations in 4 genes that serve a fundamental cellular 
function cause a distinct renal-neuronal disease phenotype. It is important to note that none 
of the affected individuals with autosomal recessive mutations carried two truncating alleles 
in the mutated gene (Supplementary Table 1).
Brain phenotype in zebrafish and mouse models
To evaluate the pathogenic effects of KEOPS protein loss of function in an in vivo animal 
model we performed CRISPR/Cas9 knockout of the orthologous zebrafish genes osgep, and 
tprkb. Knockout of osgep (Supplementary Fig. 5) or tprkb (Supplementary Fig. 6) in 
zebrafish larvae recapitulated a microcephaly phenotype as encountered in humans with 
KEOPS gene mutations. Head size reduction was not secondary to growth retardation, since 
the body length was not reduced compared to the control groups for neither gene 
(Supplementary Fig. 5–6). Because most patients with OSGEP mutations died in early 
childhood, we generated Kaplan-Meyer-survival curves for zebrafish with CRISPR/Cas9 
knockout of osgep or tprkb and found that knockout fish show early lethality 
(Supplementary Fig. 7). In particular, all homozygous larvae died within 15 or 18 days post 
fertilization for osgep and tprkb, respectively.
We then examined an embryonic mouse model for recapitulation of human GAMOS 
phenotypes. Mouse embryos with CRISPR/Cas9 knockout of Lage3, Osgep, or Tprkb had 
significantly reduced cortex length, cortex – midbrain midline length, and cortex width, and 
thus reproduced the human microcephaly phenotype (Supplementary Fig. 8).
We did not observe a renal phenotype in knockout mice or fish. We hypothesize that this is 
due to early lethality masking renal involvement that might occur in older animals.
Functional and structural assessment of the mutations in the KEOPS complex
Using the available crystal structures of homologous subassemblies of the KEOPS complex, 
19–21
 we constructed a 3D model of the human complex. The subunits are arranged in a 
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linear fashion in the order LAGE3-OSGEP-TP53RK-TPRKB (Fig. 2a). OSGEP constitutes 
the catalytic subunit of the complex while the other subunits are obligatory for t6A 
modification, but their biochemical contribution is not understood.19,20 Projection of the 
various mutations onto the 3D model of KEOPS and incorporation of the sparse mechanistic 
knowledge of the complex (Fig. 2a),7,8,19,20 led us to classify the mutations into three 
classes according to their putative biochemical effects: (1) those that might perturb folding 
and/or protein interaction (LAGE3: Val106Phe; OSGEP: Val107Met, Lys198Arg, 
Arg247Gln, Arg280His; TP53RK: Thr81Arg; TPRKB: Leu136Pro, Tyr149Cys) (2) those 
that might perturb interaction with the tRNA substrate (OSGEP: Arg325Trp/Gln; TP53RK: 
Arg243Leu), and (3) those in residues near the essential histidines in the active site of 
OSGEP (Ile14Phe, Cys110Arg, Ile111Thr) that may weaken catalytic activity. Using a 
yeast-based functional growth complementation assay (Fig. 2b) two functional classes of 
OSGEP mutant alleles were identified: Hypomorphic alleles that restore growth but to a 
lesser extent than the wild-type OSGEP, and amorphic alleles that completely fail to restore 
growth. Mutations corresponding to hypomorphic alleles (Lys198Arg, Arg247Gln, 
Arg280Cys and Arg325Gln) are localized mostly in regions involved in interactions with the 
Pcc1 (Lage3) and Bud32 (TP53RK) subunits, leading to a mild phenotype. Conversely, 
mutations corresponding to amorphic alleles (Ile14Phe, Ile111Thr and Cys110Arg) are in 
close vicinity to the catalytic cleft residues, resulting in a severe phenotype.
Furthermore, we show by co-immunoprecipitation experiments that the truncating mutation 
p.Lys60Serfs*61 and the missense mutation p.Thr81Arg of TP53RK detected in the siblings 
of family B77 both abrogated the interaction between TPRKB and TP53RK (Fig. 2c). Other 
mutations of any of the 4 genes did not abrogate intermolecular interactions (Supplementary 
Fig. 9–11).
Role of KEOPS proteins in cell proliferation and DDR
We first evaluated subcellular localization of all 4 KEOPS proteins, either endogenous or 
overexpressed as Myc- or GFP-tagged proteins. We found that all 4 proteins localize both to 
the cytoplasm and the nucleus in podocyte cell lines (Supplementary Fig. 12–13). 
Furthermore, we demonstrated by mass spectrometry in a human podocyte cell line stably 
over-expressing LAGE3 as well as by coimmunoprecipitation in HEK cells that all three 
subunits co-purified with LAGE3 indicating that a complete KEOPS complex is formed in 
human cell lines (Supplementary Fig. 14).
Genetic deletion of KEOPS genes results in severe growth defects in yeast.12 We therefore 
tested whether knockdown of OSGEP, TP53RK, or TPRKB also altered proliferation of 
mammalian cells and found that stable knockdown of these genes in human podocytes 
impaired cell proliferation rate using a BrdU assay (Fig. 2d) and the XCELLigence® system 
(Supplementary Fig. 15A). The proliferation defect was rescued by reexpressing wildtype 
but not mutant proteins of the respective mouse cDNAs (Fig. 2e–f; Supplementary Fig. 15B) 
showing that the identified human disease alleles impair protein functionality.
We observed that after 4–5 passages human podocyte cell lines with stable knockdown of 
OSGEP, TP53RK, or TPRKB exhibited severely reduced cell survival and increased 
apoptosis as demonstrated by elevated caspase-3 activity (Fig. 3a). Because the KEOPS 
Braun et al. Page 4
Nat Genet. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
complex has been implicated in genome maintenance,13,14 we tested whether the observed 
induction of apoptosis could be elicited by activation of DNA damage response signaling 
(DDR). We found that stable knockdown of OSGEP, TP53RK, or TPRKB in human 
podocyte cell lines increased immunofluorescence staining for γH2AX, indicating DDR 
activation (Fig. 3b, Fig. Supplementary Fig. 16A). We confirmed increased γH2AX by 
immunoblotting in knockdown podocyte cell lines (Fig. 3c–d, Supplementary Fig. 17) and in 
fibroblasts from patients with GAMOS and mutations of OSGEP or TPRKB 
(Supplementary Fig. 16B).
DDR activation results in cell cycle arrest in order to allow DNA repair, if possible. 
Alternatively, if DNA damage is too severe, induction of apoptosis avoids propagation of 
cells with damaged genetic material. In order to elucidate the sequence of DDR activation 
and induction of apoptosis, we performed immunoblotting of γH2AX, and caspase-3 at 3 
different time points after stable knockdown of OSGEP in human podocyte cell lines (Fig. 
3c–d). We found increased protein levels of γH2AX and the CDK inhibitor p21 on days 5, 
7, and 9 after knockdown. Conversely, the proapoptotic factor BAX and cleaved Caspase-3 
only showed strong induction on days 7 and 9 (Fig. 3c–d). The time course suggested that, 
as expected, γH2AX activation precedes induction of apoptosis. Induction of γH2AX, p21, 
BAX, and caspase-3 were also found in podocytes with stable knockdown of TP53RK or 
TPRKB (Supplementary Fig. 17). We further confirmed genomic instability in KEOPS 
knockdown cells by showing that the genotoxic agent mitomycin-C induced apoptosis in 
OSGEP, TP53RK, or TPRKB knockdown cell lines at concentration that did not affect 
control cells (Supplementary Fig. 18). To further elucidate the role of KEOPS proteins in 
DDR, we characterized an antibody against TP53RK in rat kidney sections (Supplementary 
Fig. 19–20) and found that TP53RK colocalizes with the DNA repair protein PARP1 in renal 
glomeruli (Figure 3e). Similarly, we found colocalization of OSGEP and PARP1 in human 
podocyte cell lines (Supplementary Fig. 20C). Co-immunoprecipitation experiments in 
HEK293T cells demonstrated that all four members of the KEOPS complex precipitate 
endogenous PARP1 (Figure 3f) suggesting a potential link between KEOPS and PARP1 
function that might contribute to the induction of DDR seen upon knockdown of KEOPS 
genes.
Microcephaly is a feature common to various syndromes of defective DDR22–25 likely due 
increased apoptosis of neuronal progenitor cells. Furthermore podocyte loss has been 
described as an important pathomechanism of renal glomerulosclerosis.26 We therefore 
propose that induction of DDR and increased apoptosis are likely an integral part of the 
pathogenesis of GAMOS in individuals with mutations in KEOPS genes.
Although it has been shown in yeast that mutants of KEOPS subunits exhibit shortened 
telomeres27 and some patients with microcephaly have shortened telomeres,28 telomere 
length of affected children was in the normal range for their age and in comparison with 
their parents, suggesting that the KEOPS complex mutations do not affect telomere 
maintenance (Supplementary Fig. 21).
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Regulation of podocyte actin cytoskeleton organization by the KEOPS complex
Upon EGF stimulation, OSGEP and TP53RK were suggested to interact with proteins of the 
ARP2/3 complex,29 which are essential regulators of actin remodeling at lamellipodia.30 In 
this context it is of interest that lamellipodia formation and actin remodeling are considered 
important cellular functions of podocytes and are impaired in monogenic forms of SRNS.31 
We thus first confirmed by coimmunoprecipitation in HEK293T cells that OSGEP and 
TP53RK interacted with 4 ARP complex proteins, namely ARPC1B, ARPC2, ACTR2, and 
ACTR3 (Fig. 4a–c and Supplementary Fig. 22).
We then found that upon EGF stimulation, which induces formation of the sub-lamellipodia 
actin network, OSGEP and TP53RK colocalized with ARP2 and ARP3 at lamellipodia in 
human podocytes (Fig. 4d). Interestingly, in OSGEP and TP53RK knockdown podocyte cell 
lines the formation of the sub-lamellipodia actin network was severely disrupted (Fig. 4e), a 
finding that is likely relevant for the SRNS pathogenesis.
We then studied podocyte migration, a well-established surrogate phenotype of SRNS, that 
is typically altered upon loss-of-function of genes that if mutated cause monogenic forms of 
SRNS.32–34 We found that podocyte migration, assessed in a scratch wound assay, was 
reduced in podocytes with knockdown of OSGEP, TP53RK, and TPRKB (Fig. 4f). We 
conclude that the KEOPS proteins OSGEP and TP53RK play a role in actin regulation, 
lamellipodia formation, and cell migration, and that these mechanisms likely contribute to 
the pathogenesis nephrotic syndrome upon alterations of KEOPS proteins.
In conclusion, we have demonstrated that specific mutations in genes encoding the four 
subunits of the KEOPS complex are newly identified monogenic causes of GAMOS. We 
delineate impaired cell proliferation, increased apoptosis, genomic instability, and defects in 
actin regulation as possible pathogenic features.
ONLINE METHODS
Study participants
We obtained blood samples and pedigrees following informed consent from individuals with 
NS / GAMOS or their legal guardians. Approval for human subjects research was obtained 
from Institutional Review Boards of the University of Michigan, Boston Children’s 
Hospital, the University of Erlangen, and the Comité de Protection des Personnes Ile de 
France II.
Homozygosity mapping and whole exome sequencing
Whole exome sequencing was performed as described previously1 using Agilent 
SureSelect™ human exome capture arrays (Thermo Fisher Scientific) with next generation 
sequencing (NGS) on an Illumina™ platform. Sequence reads were mapped against the 
human reference genome (NCBI build 37/hg19) using CLC Genomics Workbench (version 
6.5.1) (CLC bio). For homozygosity mapping, downstream processing of aligned BAM files 
were done using Picard and samtools.2 SNV calling was done using GATK5 and the 
generated VCF file was subsequently used in homozygosity mapper.3 Genetic regions of 
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homozygosity by descent were plotted across the genome as candidate regions for recessive 
genes as previously described.4 Mutation calling was performed in line with proposed 
guidelines5 by scientists, who had knowledge of clinical phenotypes, pedigree structure, and 
genetic mapping.
High-throughput mutation analysis by array-based multiplex PCR and NGS
We utilized the 48.48 Access Array microfluidic technology (Fluidigm™) to perform 
barcoded multiplex PCR as described previously.6,7 A total of 91 individuals with NS and 
brain anomalies as well as 816 individuals with isolated NS were sequenced. 2 x 250bp 
paired-end sequencing was performed on an Illumina™ MiSeq instrument. Sequence 
alignment was conducted using CLC Genomics Workbench (CLC bio). Mutations were 
confirmed by Sanger sequencing and evaluated for segregation.
Generation and phenotypic characterization of stable zebrafish knockout lines by CRISPR/
Cas9
Target selection and sgRNA generation—Single guide RNA (sgRNA) targets were 
selected using the CHOPCHOP online tool (https://chopchop.rc.fas.harvard.edu8) following 
their ranking algorithm. The algorithm takes in to account all potential off-targets differing 
in up to 2 nucleotides, GC-content and presence of a guanine residue in the last position 
before the Protospacer Adjacent Motif (PAM) sequence since these factors influence the 
efficiency of sgRNA binding and Cas 9 cleavage.9 Targets were chosen in the early exons to 
potentially introduce early frameshift mutations to maximize loss of function of the protein. 
gRNAs were generated by in-vitro transcription from oligonucleotide based templates using 
the MEGAscript T7 Transcription kit (Ambion) as described before.9 Since gRNA activity is 
higher if 2 Guanine bases follow the T7 promotor, template sequences were modified 
accordingly if necessary. The resulting change of one or two nucleotides in the 5’ end of the 
gRNA results in a higher indel frequency9 and does not reduce specificity.10
Microinjection, mutation analysis and breeding—2 μl of sgRNA stock (500 ng/μl) 
were mixed with 2 μl of recombinant Cas 9 protein (1 μg/μl, PNA Bio, Thousand Oaks, CA) 
and incubated on ice for at least 10 min to allow formation of the sgRNA/Cas9 complex. 2 nl 
of the injection mix was injected intracellular in one cell stage zebrafish embryos using glass 
needles and a micromanipulator. DNA was extracted from 10 pooled injected embryos and 
an uninjected control group at 48 hours post fertilization using the HotShot protocol.11 
Mutagenesis was determined by a T7 endonuclease assay as described before.12 Positive 
clutches (F0 generation) were raised to adulthood and outcrossed against wildtype fish. 
Germline transmission was also determined by the T7 endonuclease assay. Positive clutches 
(F1 generation) were raised to adulthood and genotyped individually. Fish carrying the same 
mutation were pooled being the founders of the heterozygous stable knock out line.
Microcephaly assay in Zebrafish—Zebrafish larvae at 4 days post fertilization (dpf) 
were embedded in 1% ultra-low gelling temperature agarose (Type IX-A, Sigma-Aldrich, St. 
Louis, MO) and imaged under a microscope (Zeiss, Germany) from a dorsal view. Total 
body length and head diameter through the rear third of the eye lens were measured using 
ImageJ, the measuring person being blinded for the genotype. Head diameter to total body 
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length ratio was calculated as an index for microcephaly. Significant differences were 
calculated using the one-way ANOVA test with multiple comparisons and a standard 
confidence interval of 95%.
Generation and phenotypic characterization of transient KEOPS mutant mouse embryos 
by CRISPR/Cas9
The murine genomic regions equivalent to the human mutations in LAGE3 (Phe137Ser), 
OSGEP (Ile14Phe), TP53RK (Arg243Leu) and TPRKB (Leu136Pro) genes were analyzed 
for CRISPR/Cas9 target sites using the software package Spacer Scoring for CRISPR (SSC) 
(http://crispr.dfci.harvard.edu/SSC), and “Optimized CRISPR Design” tool (http://
crispr.mit.edu/). Four different sgRNAs, each one targeting a different KEOPS gene were 
selected based on efficiency score and low off-target effect. sgRNA were synthesized in vitro 
following standard procedures and Cas9 mRNA was purchased from Sigma 
(Cas9mRNA-1EA). A mix of sgRNA (100 ng/μL) and Cas9mRNA (100 ng/μL) for each 
gene or a scramble sg RNA for Ctl embryos (WT) was co-injected into the cytoplasm of 
fertilized eggs and transferred into pseudopregnant females. Transient CRISPR/Cas9 E18.5 
embryos were recovered and analyzed for microcephaly phenotypes. The occurrence of gene 
editing was confirmed by PCR amplification from extracted genomic DNA, followed by 
Sanger sequencing. Targeting efficiency was quantified by the Tracking of Indels by 
Decomposition (TIDE) web tool. Brain morphology and microcephaly phenotype was 
assessed by measuring cortex length, cortex midbrain midline length, and cortex width for 
WT and targeted CRISPR embryos. Statistical analysis was performed by using GraphPad 
Prism software version 6.0. An unpaired Student t-test was used to test for differences 
between the means.
3D modeling
3D models of the human KEOPS complex were obtained using the Phyre server (http://
www.sbg.bio.ic.ac.uk/phyre2/html/).13 The highest confidence models were retrieved for the 
LAGE3, OSGEP and TP53RK components. The structure of the human TPRKB protein was 
available at the PDB (code 3ENP). The model of the human KEOPS was constructed by 
superposing the structures of the human subunits onto the archaeal Pcc1/Kae1 (PDB code 
3ENO) and Kae1/Bud32 (PDB code 3VWB) and the fungal Bud32/Cgi121 (PDB code 
4WW9) subcomplexes. The sequences and structures of the interfaces between the subunits 
are well conserved. The LAGE3 Phe137Ser and TP53RK Gly42Asp mutations fell out of 
sequence regions that could be confidently modeled and are therefore not represented on 
Figure 2a.
Heterologous complementation assay of yeast Δkae1 mutant
The haploid conditional yeast kae1 mutant strain (DL344) was derived from W303 genetic 
background and contains a genomic deletion of KAE1 gene complemented by an URA3-
plasmid borne KAE1 wild type allele (kindly provided by Domenico Libri, Institut Jacques 
Monod, Paris, France). Human cDNAs encoding wildtype or mutant OSGEP were cloned in 
the yeast multicopy vector pESC-TRP1 (Agilent technologies) under the control of the yeast 
strong inducible promoter PGAL10. Native pESC-TRP1 plasmid and a pFL39 plasmid 
carrying the yeast wild-type KAE1 gene were used as negative and positive controls, 
Braun et al. Page 8
Nat Genet. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
respectively. The various plasmids were introduced in the kae1 mutant strain. After selection 
on glucose-Trp solid medium, transformant clones were streaked onto Gal-Trp + 5FOA 
medium to chase out the URA3-KAE1 plasmid. Serial dilutions of cell suspensions prepared 
from colonies growing of 5FOA plates were spotted on Gal-Trp medium and incubated at 
28°C to monitor growth complementation. Expression of human OSGEP constructs was 
confirmed by western blot using an anti-OSGEP antibody (HPA039751, Sigma Life 
Science) (Supplementary Fig. 23)
Proteomic studies
A human podocyte cell line stably expressing the human LAGE3 subunit fused to N-
terminal V5 epitope was used to perform proteomic studies. Co-immunoprecipitation was 
performed using μMACS Protein A Microbeads Isolation Kit (Miltenyi Biotec) for the 
isolation of V5- tagged LAGE3. Briefly, podocytes cell lysates containing 1.5 mg of protein 
were incubated with 2 μg of mouse anti-V5 antibodies (Bio-Rad, MCA1360) for one hour at 
4°C followed by 30 minutes incubation with 50 μl of Protein A Microbeads and finally 
applied onto μMACS Separation Columns (Miltenyi Biotec). Protein isolation was further 
performed according to the manufacturer’s recommendations. The immunoprecipitation 
eluates were processed by FASP as described in Lipecka et al. (2016).14 Peptides were dried 
in a Speedvac and resuspended in 10% acetonitrile (ACN), 0.1% TFA prior nanoRSLC-Q 
exactive Orbitrap Plus MS analysis (Dionex RSLC Ultimate 3000, Thermo Fisher 
Scientific). Raw files were analyzed using MaxQuant 1.5.5.1 software15 against the Human 
Uniprot KB/Swiss-Prot database 2016-01. The false discovery rates (FDRs) at the protein 
and peptide level were set to 1%. Scores were calculated in MaxQuant as described 
previously.15 Statistical and bioinformatic analysis, including volcano plot, were performed 
with Perseus software version 1.5.5.3 (freely available at www.perseus-framework.org).16 
For statistical comparison, two groups were set up, each containing 3 biological replicates: 
control IP and IP LAGE3. Only proteins that were quantified at least 3 times out of 6 were 
retained. T-test was performed and the data were represented on a volcano plot (FDR<0.01, 
S0=2, 250 randomizations) (Supplementary Fig. 14).
cDNA cloning
Human LAGE3, OSGEP, TP53RK, and TPRKB full-length cDNA were subcloned by PCR 
from human full-length cDNA (NM_006014.4, NM_017807.3, NM_033550.3, 
NM_016058.2). Mouse Osgep, Tp53rk, Tprkb were subcloned by PCR from human full-
length cDNA (NM_133676.2, NM_023815.4, NM_001170488.1). Human ARPC1B, 
ARPC2, ACTR2, and ACTR3 were subcloned by PCR from human full-length cDNA 
(NM_005720.3, NM_005731.3, NM_001005386.2, NM_005721.4). cDNA was subcloned 
into the pENTR-D-TOPO vector (Thermo Fisher). Subsequently, expression vectors were 
generated using LR clonase (Thermo Fisher) following the manufacturer’s instruction. The 
following expression vectors were used in this publication: pRK5-N-Myc, pCDNA6.2-N-
GFP (Thermo Fisher), pDEST69-N-FLAG, pLenti-V5-DEST™ (Thermo Fisher), and 
pSirenRetroQ (Clontech). Clones reflecting the mutations identified in individuals with 
SRNS were introduced in the cDNA constructed using the Quick change II XL site-directed 
mutagenesis kit (Agilent Technologies) following the manufacturer’s instructions. cDNAs 
were subcloned into the pENTR-D-TOPO or pDONOR221 vector (Thermo Fisher). 
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Subsequently, expression vectors were generated using LR clonase (Thermo Fisher) 
following the manufacturer’s instruction. The following expression vectors were used in this 
publication: pRK5-N-Myc, pCDNA6.2-N-GFP (Thermo Fisher), pDEST69-N-FLAG, 
pLenti-V5-DEST™ (Thermo Fisher), and pSirenRetroQ (Clontech). Clones reflecting the 
mutations identified in individuals with GAMOS were introduced in the cDNA constructed 
using the Quick change II XL site-directed mutagenesis kit (Agilent Technologies) 
following the manufacturer’s instructions.
Primary Antibodies (Validation: Supplementary Fig. 24–25)
Target protein Company Catalogue # Species Dilution (IF) Dilution (WB)
LAGE3 LS Bioscience LS-C201798 Rabbit 1:200 1:1,000
OSGEP Novus biologicals NBP2-00823 Mouse 1:400 1:1,000
TP53RK Abgent AP17010b-ev Rabbit 1:200 1:1,000
TP53RK Santa Cruz Biotechnology sc-85846 Goat 1:100 1:1,000
TPRKB Abcam ab128112 Mouse 1:200 n/a
TPRKB Abcam ab96261 Rabbit n/a 1:1,000
ARP2 Abcam ab128934 Rabbit 1:200 1;1,000
Phospho-Histone H2A.X Cell Signaling (#9718) Rabbit 1:200 1;1,000
Histone H2A.X Cell Signaling (#2595) Rabbit n/a 1;1,000
PARP1 Sigma Aldrich HPA045168 Rabbit 1:200 1;1,000
p21 Waf1/Cip1 Cell Signaling (#2947) Rabbit n/a 1;1,000
BAX Cell Signaling (#5023) Rabbit n/a 1;1,000
Cleaved Caspase-3 (Asp175) Cell Signaling (#9661) Rabbit n/a 1;1,000
Synaptopodin American Research Products #03-65194 Mouse 1:200 n/a
WT1 Santa Cruz Biotechnology sc-192 Rabbit 1:100 n/a
Immunofluorescence and confocal microscopy in cell lines and tissue sections
Immunostaining was performed as described previously in immortalized human podocytes 
cell lines. Overexpression experiments were performed 24–48 hrs after transfection with 
Lipofectamine2000®. Immunostaining followed a standard protocol using permeabilization 
with 0.1% SDS for cells and 0.025 %Triton-X100 for paraffin embedded tissue sections (rat 
kidney, day 1 postpartum). Confocal imaging was performed using Leica SP5X system with 
an upright DM6000 microscope and images were processed with the Leica AF software 
suite. For lamellipodia staining (Figure 4) cells were grown at 37°C (non-permissive 
temperature) for 7 days, and were stimulated with recombinant Epidermal Growth Factor 
(EGF, Thermo Fisher) at a concentration of 100 ng/ml 20 min before staining. 
Immunofluorescence experiments were performed at least twice independently. 
Representative images are shown.
RNAi knockdown in human podocyte cell lines
pSirenRetroQ with shRNA against human OSGEP, TP53RK, and TPRKB was used for 
retroviral transduction of immortalized human podocyte cell lines (Dr. Moin Saleem, Bristol, 
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UK). Puromycin selected transduced cells. Due to growth defects, knockdown cells 
deteriorated after passage 4–5 (typically 12–14 days after transduction). Knockdown 
efficiency was confirmed for all experiments (Supplementary Fig. 24). For rescue 
experiments knockdown podocytes underwent a second lentiviral transduction with mouse 
mutant or wildtype cDNA of Osgep, Tp53rk, or Tprkb, respectively. (Expression control: 
Supplementary Fig. 26).
shRNA targets
Gene shRNA target sequence
OSGEP (NM_017807.3) shRNA# 1 GGTGTAATGTGAGGCTACAGGAGAT
shRNA# 2 GGATTAACCTCCCAGGATATC
TP53RK (NM_033550.3) shRNA# 3 GCTGAACATTGTGCTCATAGA
shRNA# 5 GCTGAGTTTCATTTCAGCACT
TPRKB (NM_016058.2) shRNA# 1 GCTGGACCTATTTCCCGAATG
shRNA# 2 GCAGTTCACCTCTACAAACTG
Podocyte proliferation assay
The proliferation assay was performed using the xCELLigence systemTM with E-plates 16 
(Roche Applied Science) according to the manufacturer’s instructions. Experiments were 
performed 7 days after retroviral knockdown and 48 hrs after rescue transduction (if 
applicable), passage 4. For each condition, 2.5 x 104 cells were seeded in each well of the E-
plate 16. Changes in impedance were analyzed using the RTCA software. Results were 
plotted as cell index (relative podocyte proliferation) vs. time. Each experiment was 
performed in triplicates, and repeated at least two times independently. Results are presented 
as mean ± standard deviation.
Colorimetric proliferation assay (BrdU incorporation)
Proliferation rate was assessed using a colorimetric BrdU assay kit (#6813, Cell signaling) 
according to the manufacturer’s instructions. Experiments were performed in human 
immortalized podocytes 7 days after retroviral shRNA knockdown of OSGEP, TP53RK, or 
TRPKB (passage 4). BrdU incorporation is measured as absorbance at 450 nm using a 
spectrophotometer. Data is plotted as mean and standard deviation. Statistical significance 
was calculated using one-way ANOVA multi-test analysis with post hoc testing according to 
Sidak. P values <0.01 and <0.05 were considered statistically significant and are indicated in 
the figures. Measurements were performed in triplicates, and experiments were repeated 
twice independently.
Apoptosis assay and treatment with Mitomycin-C
Apoptosis in human podocyte cell lines with stable knockdown of OSGEP, TP53RK, and 
TPRKB was assessed using a colorimetric Caspase 3 Assay Kit (abcam, ab39401) following 
the manufacturer’s instructions. Caspase-3 activity is measured as absorbance at 405 nm 
using a spectrophotometer. Data is plotted as mean and standard deviation. Statistical 
significance was calculated using one-way ANOVA multi-test analysis with post hoc testing 
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according to Sidak. P values <0.01 and <0.05 were considered statistically significant and 
are indicated in the figures. Individual measurements were performed in duplicates, and 
experiments were repeated three times independently. For Mitomycin-C (MMC) 
experiments, knockdown and control cells were treated with MMC (2.5 μg/ml) 12 hours 
prior to the experiment.
Podocyte migration assay
The migration rate of human podocyte cell lines with retroviral shRNA mediated 
knockdown of OSGEP, TP53RK, and TPRKB (5 days after knockdown, passage 3) was 
examined using the IncuCyte™ video-microscopy system (Essen Biosciences). For this 
assay, cells were seeded on a 96 well plate, grown to confluency, and a standardized scratch 
wound was made using the Woundmaker™ device as per protocol. Using live cell imaging 
wound closure was recorded in an hourly interval until the wound was fully closed. 
Subsequent data analysis was performed using the IncuCyte™ 96-well Kinetic Cell 
Migration and Invasion Assay software module. Individual data points are presented as mean 
± standard deviation resulting from at least triplicate measurements. Experiments were 
repeated three times independently.
Telomeric Restriction Fragment
Measurement of the length of the terminal restriction fragments was performed by Southern 
blotting as previously described.17
Statistical analysis
Statistical analysis was performed using Graph Pad Prism®. Significances were calculated 
using unpaired one-way ANOVA with multiple comparisons and a standard confidence 
interval of 95%. Post hoc analysis was performed according to Sidak. P values <0.01 and 
<0.05 were considered statistically significant and are indicated in the figures.
Densitometry analysis of immunoblots
Densitometry analysis was performed using ImageJ.
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Figure 1. Whole exome sequencing identifies recessive mutations in the 4 KEOPS complex 
encoding genes LAGE3, OSGEP, TP53RK, TPRKB in 30 families with GAMOS 2–5
(a–d) Left or upper panels show clinical phenotype of individuals with recessive 
mutations, right or lower panels show exon structures and secondary structures of 
human LAGE3 (a), OSGEP (b), TP53RK (c), and TPRKB (d) cDNA. Positions of start 
codons and of stop codons are indicated. Predicted secondary structure is indicated for beta 
strand and α-helix conformation as triangle and zigzag lines, respectively.
(a) Clinical features of individual B60 with a hemizygous mutation of LAGE3: Renal 
histology showing FSGS, transmission electron microscopy (TEM) showing podocyte foot 
process effacement (arrowheads), and MRI showing microcephaly with polymicrogyria and 
diffuse cerebellar atrophy.
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(b) Clinical features of individuals ‘DC’, B80, B58, and B377 with mutations of 
OSGEP: Renal histology of individual ‘DC’ showing FSGS, and TEM of B80 showing foot 
process effacement (arrow heads). Cranial imagining of individuals B58 and B377 showing 
microcephaly, reduced gyration, and diffuse cortical atrophy. Clinical photograph of B58 
showing severe deformation of the forehead.
(c) Clinical features of individual B77_22 with compound heterozygous mutations of 
TP53RK: Cranial imaging showing microcephaly and polymicrogyria.
(d) Clinical features of individual B1144 with a homozygous mutation of TPRKB: Renal 
histology showing FSGS and TEM showing podocyte foot process effacement (arrow 
heads). Brain MRI showing microcephaly and pachygyria. HEMI, hemizygous; het, 
heterozygous; HOM, homozygous.
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Figure 2. TP53RK mutations abrogate interaction with TPRKB, and GAMOS mutations fail to 
rescue cell proliferation rate decreased by knockdown of OSGEP or TP53RK
(a) Structural modeling of KEOPS mutations. The three-dimensional representation of 
the human KEOPS complex is based on structural information of subcomplexes from 
archeae and yeast. Subunits are represented in different colors: LAGE3 (green), OSGEP 
(yellow), TP53RK (red) and TPRKB (blue). The residues corresponding to missense 
mutations identified in patients with GAMOS2–5 are mapped as black spheres and their 
corresponding positions are written in green (LAGE3), black (OSGEP), red (TPR53K) and 
blue (TPRKB). A model of a nucleotide bound in the active site of OSGEP is represented as 
cyan spheres.
(b) Overexpression of human OSGEP in a Δkae1 (orthologous yeast gene) yeast strain 
partially rescues the Δkae1 associated growth defect. Each horizontal panel corresponds to 
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tenfold serial dilution of the cell suspension. The extent of growth complementation was 
assessed by comparison with full complementation (KAE1) and no complementation (none). 
Overexpressed alleles are indicated on the left. Mutants OSGEP alleles fall into two classes: 
hypomorphic alleles (Lys198Arg, Arg247Gln, Arg280Cys, Arg325Gln) and amorphic 
alleles (Ile14Phe, Ile111Thr, Cys110Arg).
(c) Co-immunoprecipitation of FLAG-tagged full-length wildtype TPRKB with GFP-tagged 
wildtype TP53RK or mutant TP53RK cDNA constructs that reflect the GAMOS mutations. 
Constructs reflecting the TP53RK mutants p.Lys60Serfs*61 and p.Thr81Arg abrogate 
interaction with TPRKB.
(d) A colorimetric BrdU assay demonstrates that human podocytes with stable knockdown 
of OSGEP, TP53RK, and TPRKB exhibit reduced cell proliferation rates. Cells are at 
passage 3 after transduction, * indicates p<0.05, **indicates p<0.01 calculated by one-way 
ANOVA.
(e–f) Proliferation rate of human immortalized podocytes was assayed using the 
xCELLigence® system. Cells are at passage 4 after stable transduction with shRNA 
targeting OSGEP and TP53RK.
(e) OSGEP knockdown reduced podocyte proliferation rate (red), which was rescued by 
stable overexpression of mouse wildtype, full-length Osgep (green), but not of mutant 
constructs reflecting the mutations identified in individuals with GAMOS.
(f) TP53RK knockdown reduced podocyte proliferation rate (red), which was rescued by 
stable overexpression of mouse wildtype, full-length Tp53rk (green), but not of mutant 
Tp53rk constructs reflecting the mutations identified in individuals with GAMOS.
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Figure 3. Knockdown of OSGEP, TP53RK, or TPRKB in human podocytes induces DNA damage 
response signaling (DDR) and subsequently apoptosis
(a) In a colorimetric assay, knockdown of OSGEP, TP53RK, or TPRKB in human 
podocytes increases caspase-3 activity indicating apoptotic cell death. Cells are at passage 4 
after transduction, **indicates p<0.01 calculated by one-way ANOVA.
(b) Staining with an antibody against phosphorylated histone H2A.X (γH2AX) was 
increased in human podocytes 7 days after stable shRNA knockdown of OSGEP, TP53RK, 
or TPRKB (passage 3) as compared to scrambled control cells indicating induction of DDR. 
DAPI stains DNA (blue). Scale bar 10μm. Quantification of 100 cells for each condition is 
shown in Suppl. Fig. 16A.
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(c) Compared to scrambled shRNA transfected control cells, knockdown of OSGEP in 
human podocytes increases γH2AX and CDK inhibitor p21 on days 5, 7, and 9 after 
knockdown. Strong increase of the proapoptotic factor BAX and cleaved caspase-3 is only 
observed on days 7 and 9.
(d) Densitometry of the intensity of immunoblot signals of γH2AX, p21, BAX, and cleaved 
caspase-3 in human immortalized podocytes cell lines was measured using ImageJ. Absolute 
values were normalized to beta actin (loading controls). Intensities of scrambled control 
cells (black) were normalized as 1. Data points are presented as mean of two OSGEP 
shRNAs and standard deviation. Knockdown of OSGEP results in an increase of γH2AX 
and p21 on days 5,7, and 9 after knockdown. In contrast, BAX and cleaved caspase-3 only 
show strong induction on days 7 and 9 after transduction demonstrating that the activation of 
DDR (γH2AX) precedes the induction of apoptosis (BAX, cleavage of caspase-3) upon 
knockdown of OSGEP. The decrease of signals for γH2AX, p21, and BAX on day 9 is 
likely explained by apoptotic cell death.
(f) Staining of renal rat sections (p1) with antibodies against PARP1 and TP53RK 
demonstrates that both proteins colocalize to PARP1 positive nuclear foci in renal glomeruli. 
DAPI stains DNA (blue). Scale bars are 7.5 μm.
(g) Upon overexpression Flag-tagged LAGE3, OSGEP, TP53RK, and TPRKB 
immunoprecipitate endogenous PARP1 in HEK293T cells.
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Figure 4. OSGEP and TP53RK colocalize with the ARP2/3 complex at lamellipodia of podocytes, 
and knockdown disrupts the actin cytoskeleton and impairs cell migration
(a–b) Upon co-overexpression in HEK293T cells GFP-tagged OSGEP (a) and TP53RK (b) 
interact with 4 FLAG-tagged proteins of the ARP2/3 complex, namely ARPC1B, ARPC2, 
ACTR2, and ACTR3.
(c) Half-endogenous co-immunoprecipitation of GFP-tagged OSGEP and TP53RK confirms 
interaction with endogenous ARP2 in HEK293T cells.
(d) Upon EGF stimulation (100 ng/ml, 20 min) to induce lamellipodia formation, OSGEP 
(red) and TP53RK (red) co-localize with ARP2 (green) and ARP3 (green) at lamellipodia of 
differentiated human podocytes. The panels show a 100 x magnification of lamellipodia. 
Scale bars are 7.5 μm.
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(e) Upon EGF stimulation (100 ng/ml, 20 min) of differentiated podocytes, actin stress fibers 
(labelled red with α-ACTN4 antibody) radiate as actin fans to support the sub-lamellipodia 
network (white bracket). Note that in OSGEP and TP53RK knockdown cell lines the 
formation of the actin fan supporting lamellipodia is severely disrupted. Scale bars are 7.5 
μm. Cells are at passage 3 after stable transduction with shRNA targeting OSGEP or 
TP53RK, respectively.
(f) Cell migration rate of human immortalized podocytes was assessed using the IncuCyte™ 
system to measure wound closure as representing podocyte migration rate in real-time. 
45,000 cells were seeded for each condition. Experiments are performed 5 days after stable 
transduction with shRNA against KEOPS genes (passage 3). Note that compared to control 
cells (black line), knockdown of OSGEP (red lines), TP53RK (green lines), and TPRKB 
(blue lines) with two different shRNAs for each gene reduced podocyte migration rate in 
vitro.
Braun et al. Page 26
Nat Genet. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Braun et al. Page 27
TABLE 1
Phenotypic spectrum in 33 individuals of 30 families with mutations of LAGE3, OSGEP, TP53RK, and 
TPRKB and Galloway-Mowat syndrome (GAMOS 2–5)
(For additional information see Supplementary Table 1.)
# of patients Median age Range
Gender Male/female 20/13
Ethnicity Asian 15
Caucasian (Iran) 4
European American 5
Hispanic 2
Arabic 3
African 1
American Indian 1
Other 2
Renal involvement Proteinuria 33/33 3 mon (n=33) At birth - 4.5 yrs
Kidney Histology 17/33
 FSGS NOS 9
 Collapsing FSGS 1
 DMS 2
 MCNS 2
 Foot process effacement NOS 2
 Other 1
 Not performed 16
ESKD 17/33 9 mon (n=16) 1 mon - 8 yrs
No ESKD before death or no data 16/33
Neurological involvement Primary microcephaly 33/33
Hypotonia 15
Spasticity 9
Developmental delay 26
Seizures / abnormal EEG 17
Gyral defects 16
Myelination defects / white matter anomalies 16
Cortical atrophy 10
Cerebellar atrophy 10
Facial dysmorphism Progeroid (old appearing) 12
Ear anomalies (large, floppy or low set) 15
Micrognathia 14
Hypertelorism 8
Skeletal features Arachnodactyly / camptodactyly 15
Short stature 7
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# of patients Median age Range
Other Intrauterine growth retardation 9
Visual impairment 6
Hearing impairment 4
Heart involvement (ASD) 3
Survival Death before 3 years of age 24 6 mon (n= 26) 6 weeks-25 yrs (n=26)
Alive at present 5
No data / death >3 yrs 4
Notes: ASD, Atrial septal defect; DMS, diffuse mesangial sclerosis; EEG, electroencephalogram; ESKD, end stage kidney disease; FSGS, focal 
segmental glomerulosclerosis; NOS, Not Otherwise Specified; IUGR, intrauterine growth restriction; MCNS, minimal change nephrotic syndrome; 
mon, months; yrs., years.
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